<?xml version="1.0" encoding="UTF-8"?>
<study api_version="0.6">
  <id>3291</id>
  <name>RNA sequencing of mouse haemopoietic cells 2014/15</name>
  <active>true</active>
  <user_id>191</user_id>
  <managers>
    <manager>
      <login>ncb</login>
      <email>ncb@sanger.ac.uk</email>
      <name>Nathalie C Smerdon</name>
      <id>191</id>
    </manager>
  </managers>
  <owners>
    <owner>
      <login>mg16</login>
      <email>mg16@sanger.ac.uk</email>
      <name>Malgorzata Gozdecka</name>
      <id>756</id>
    </owner>
  </owners>
  <!-- Family has been deprecated -->
  <family_id></family_id>
  <created_at>2014-09-04 15:13:42 +0100</created_at>
  <updated_at>2014-11-17 12:59:19 +0000</updated_at>
  <descriptors>
    <descriptor>
      <name>Study description</name>
      <value>Comprehensive analysis of AML genomes has revealed co-occurring mutations in DNA and
histone modifying enzymes suggesting their crucial role in tumourigenesis. To gain inside into
the role of those genes in AML we generated mouse models recapitulating mutations in part
of the most frequent ones. We hypothesise that aberrant chromatin modification and
underlying effect on gene expression largely contribute to leukemogenesis. To test this
hypothesis we propose to compare gene expression and DNA and histone modification in the
presence or absence of single gene mutation in mouse hematopoietic stem and progenitor
compartment in a pre-leukaemia setting. Characterisation of these models will inform the
biology of AML, identify potential therapeutic targets and provide platforms for the
assessment of novel therapeutics.


This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/</value>
    </descriptor>
    <descriptor>
      <name>Does this study contain samples that are contaminated with human DNA which must be removed prior to analysis?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>Does this study require the removal of X chromosome and autosome sequence?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>Does this study require y chromosome data to be separated from x and autosomal data before archival?</name>
      <value>false</value>
    </descriptor>
    <descriptor>
      <name>ENA Project ID</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Abstract</name>
      <value>Comprehensive analysis of AML genomes has revealed co-occurring mutations in DNA and
histone modifying enzymes suggesting their crucial role in tumourigenesis. To gain inside into
the role of those genes in AML we generated mouse models recapitulating mutations in part
of the most frequent ones. We hypothesise that aberrant chromatin modification and
underlying effect on gene expression largely contribute to leukemogenesis. To test this
hypothesis we propose to compare gene expression and DNA and histone modification in the
presence or absence of single gene mutation in mouse hematopoietic stem and progenitor
compartment in a pre-leukaemia setting. Characterisation of these models will inform the
biology of AML, identify potential therapeutic targets and provide platforms for the
assessment of novel therapeutics.
</value>
    </descriptor>
    <descriptor>
      <name>Title</name>
      <value>RNA sequencing of mouse haemopoietic cells 2014/15</value>
    </descriptor>
    <descriptor>
      <name>ENA Study Accession Number</name>
      <value>ERP006862</value>
    </descriptor>
    <descriptor>
      <name>Study Visibility</name>
      <value>Hold</value>
    </descriptor>
    <descriptor>
      <name>Do any of the samples in this study contain human DNA?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>Are all the samples to be used in this study commercially available, unlinked anonymised cell-lines?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>Study name abbreviation</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>What is the data release strategy for this study?</name>
      <value>open</value>
    </descriptor>
    <descriptor>
      <name>Will you be using WTSI's standard access agreement?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>How is the data release to be timed?</name>
      <value>standard</value>
    </descriptor>
    <descriptor>
      <name>Reason for delaying release</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Delay for</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Alignments in BAM</name>
      <value>true</value>
    </descriptor>
    <descriptor>
      <name>Please explain the reason for delaying release</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Comment regarding data release timing and approval</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Policy Url</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Policy title</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>EGA DAC Accession Number</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>EGA Policy Accession Number</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>ArrayExpress Accession Number</name>
      <value>E-ERAD-322</value>
    </descriptor>
    <descriptor>
      <name>Has the delay period been approved by the data sharing committee for this project?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>What is the reason for preventing data release?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Has this been approved?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Comment regarding prevention of data release and approval</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Data access group</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>SNP study ID</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>SNP parent study ID</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Number of gigabases per sample (minimum 0.15)</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>HMDMC approval number</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Study Type</name>
      <value>Cancer Genomics</value>
    </descriptor>
    <descriptor>
      <name>What sort of study is this?</name>
      <value>transcriptomics</value>
    </descriptor>
    <descriptor>
      <name>Reference Genome</name>
      <value>Mus_musculus (GRCm38 + ensembl_75_transcriptome)</value>
    </descriptor>
    <descriptor>
      <name>Faculty Sponsor</name>
      <value>George Vassiliou</value>
    </descriptor>
  </descriptors>
</study>
